<DOC>
	<DOCNO>NCT00842530</DOCNO>
	<brief_summary>There currently vaccine dengue specific drug treatment disease . This study aim generate information protective effect vaccine . Primary Objective To assess efficacy dengue vaccine three injection child . Secondary Objective : To evaluate reactogenicity dengue vaccine injection subgroup child .</brief_summary>
	<brief_title>Efficacy Safety Dengue Vaccine Healthy Children</brief_title>
	<detailed_description />
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 4 11 year day inclusion . Subject good health , base medical history physical examination . Provision assent form sign subject ( subject ≥ 7 year old ) inform consent form sign parent another legally acceptable representative . Subject parent/ legally acceptable representative able attend schedule visit comply trial procedure . Subject attend one school involve trial live Ratchaburi Province . For female subject childbearing potential ( girls postmenarche ) , avoid become pregnant ( use effective method contraception abstinence ) least 4 week prior first vaccination , least 4 week last vaccination . Exclusion Criteria : Febrile illness ( temperature ≥ 37.5°C ) moderate severe acute illness/infection day vaccination , accord Investigator judgment . For female subject childbearing potential ( girls postmenarche ) , know pregnancy positive urine pregnancy test day first trial vaccination . Personal family history thymic pathology ( thymoma ) , thymectomy , myasthenia . Planned participation another clinical trial present trial period . Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy , longterm systemic corticosteroid therapy . Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance . Chronic illness stage could interfere trial conduct completion , opinion Investigator . Receipt blood bloodderived product past 3 month . Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination . Receipt vaccine 4 week precede first trial vaccination . Planned receipt vaccine 4 week follow first trial vaccination.e Subject plan attend another school ( outside trial area ) move another city come 30 month .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Dengue virus</keyword>
	<keyword>Dengue fever</keyword>
	<keyword>Dengue hemorrhagic fever</keyword>
	<keyword>Dengue disease</keyword>
	<keyword>Dengue vaccine</keyword>
</DOC>